Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Sponsors: Tenaya Therapeutics; University of California, San Francisco; Brigham and Women’s Hospital; New York University; University of Colorado, Denver; Johns Hopkins University; The Cleveland Clinic; Mayo Clinic; Medical University of South Carolina; Hopital Louis Pradel; Istituti Clinici Scientifici Maugeri SpA; The Queen Elizabeth Hospital; St George’s University Hospitals NHS Foundation Trust; Royal Brompton & Harefield NHS Foundation Trust; Barts & The London NHS Trust
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 16, 2024Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Comments